ICCC ImmuCell Corp: רווח למניה לשנה מתגלגלת

ImmuCell Corporation (ICCC) is developing a biotechnological environment to support calf health by integrating proprietary antibodies into the protocols of large agribusinesses for long-term cooperation. Strict USDA oversight and high farmer loyalty secure the company's status as a niche leader. The price action for earnings per share currently stands at -20.40, while the current exchange rate already prices in the seasonal demand for veterinary biologicals.
ICCC (ImmuCell Corporation): פילוחים אנליטיים ודוחות לפי אינדיקטורים

For an investor assessing the issuer's financial stability, this metric reflects the rate of change in net profit per share over twelve months, revealing the dependence of the cost of capital on the tightness of monetary policy. By analyzing the current state of annual EPS TTM growth on GURU.Markets, one can assess how the diversification of ImmuCell Corporation (ICCC) veterinary antibodies between the meat and dairy sectors mitigates local epidemic risks, thereby supporting business margins.